HRP970528A2 - Mycosis vaccine - Google Patents
Mycosis vaccineInfo
- Publication number
- HRP970528A2 HRP970528A2 HR96115954.8A HRP970528A HRP970528A2 HR P970528 A2 HRP970528 A2 HR P970528A2 HR P970528 A HRP970528 A HR P970528A HR P970528 A2 HRP970528 A2 HR P970528A2
- Authority
- HR
- Croatia
- Prior art keywords
- dsm
- vaccine
- subspecies
- suspension
- trichophyton
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims description 242
- 206010017533 Fungal infection Diseases 0.000 title claims description 14
- 208000024386 fungal infectious disease Diseases 0.000 title claims description 8
- 239000000725 suspension Substances 0.000 claims description 210
- 241000222122 Candida albicans Species 0.000 claims description 156
- 229940095731 candida albicans Drugs 0.000 claims description 142
- 241000223229 Trichophyton rubrum Species 0.000 claims description 124
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims description 85
- 229960004906 thiomersal Drugs 0.000 claims description 85
- 238000000034 method Methods 0.000 claims description 68
- 230000002538 fungal effect Effects 0.000 claims description 66
- 210000004027 cell Anatomy 0.000 claims description 59
- 239000008103 glucose Substances 0.000 claims description 56
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 55
- 241001045770 Trichophyton mentagrophytes Species 0.000 claims description 55
- 229940041514 candida albicans extract Drugs 0.000 claims description 54
- 239000012138 yeast extract Substances 0.000 claims description 54
- 241001480043 Arthrodermataceae Species 0.000 claims description 50
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 50
- 230000037304 dermatophytes Effects 0.000 claims description 50
- 239000007864 aqueous solution Substances 0.000 claims description 46
- 102000008934 Muscle Proteins Human genes 0.000 claims description 45
- 108010074084 Muscle Proteins Proteins 0.000 claims description 45
- 239000002609 medium Substances 0.000 claims description 41
- 229920001817 Agar Polymers 0.000 claims description 38
- 239000008272 agar Substances 0.000 claims description 38
- 239000006159 Sabouraud's agar Substances 0.000 claims description 35
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 35
- 239000012449 sabouraud dextrose agar Substances 0.000 claims description 35
- 241000223238 Trichophyton Species 0.000 claims description 34
- 208000031888 Mycoses Diseases 0.000 claims description 26
- 230000002779 inactivation Effects 0.000 claims description 25
- 238000011282 treatment Methods 0.000 claims description 20
- 239000000126 substance Substances 0.000 claims description 19
- 238000004519 manufacturing process Methods 0.000 claims description 18
- 238000011321 prophylaxis Methods 0.000 claims description 14
- 241000893980 Microsporum canis Species 0.000 claims description 12
- 206010007134 Candida infections Diseases 0.000 claims description 9
- 208000010195 Onychomycosis Diseases 0.000 claims description 9
- 201000003984 candidiasis Diseases 0.000 claims description 9
- 201000005882 tinea unguium Diseases 0.000 claims description 9
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 8
- 239000001888 Peptone Substances 0.000 claims description 8
- 108010080698 Peptones Proteins 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 235000019319 peptone Nutrition 0.000 claims description 8
- 241001480037 Microsporum Species 0.000 claims description 7
- 208000007163 Dermatomycoses Diseases 0.000 claims description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 6
- 201000003929 dermatomycosis Diseases 0.000 claims description 6
- 230000000877 morphologic effect Effects 0.000 claims description 6
- 230000002519 immonomodulatory effect Effects 0.000 claims description 5
- 230000028993 immune response Effects 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 210000005253 yeast cell Anatomy 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 4
- 235000013372 meat Nutrition 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 206010061598 Immunodeficiency Diseases 0.000 claims description 3
- 230000000890 antigenic effect Effects 0.000 claims description 3
- YCHXNMPJFFEIJG-UHFFFAOYSA-N 3-methyloxiran-2-one Chemical compound CC1OC1=O YCHXNMPJFFEIJG-UHFFFAOYSA-N 0.000 claims description 2
- 230000035784 germination Effects 0.000 claims description 2
- 235000015277 pork Nutrition 0.000 claims description 2
- 230000008961 swelling Effects 0.000 claims description 2
- 238000003306 harvesting Methods 0.000 claims 6
- 238000000265 homogenisation Methods 0.000 claims 3
- 239000001963 growth medium Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims 1
- 230000000415 inactivating effect Effects 0.000 claims 1
- 238000009630 liquid culture Methods 0.000 claims 1
- 239000006285 cell suspension Substances 0.000 description 101
- 241001465754 Metazoa Species 0.000 description 92
- 208000024891 symptom Diseases 0.000 description 62
- 238000005119 centrifugation Methods 0.000 description 61
- 230000000694 effects Effects 0.000 description 56
- 239000000203 mixture Substances 0.000 description 56
- 241000700198 Cavia Species 0.000 description 55
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 53
- 230000002163 immunogen Effects 0.000 description 42
- 230000036512 infertility Effects 0.000 description 39
- 239000007927 intramuscular injection Substances 0.000 description 38
- 238000010255 intramuscular injection Methods 0.000 description 38
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 37
- 239000012153 distilled water Substances 0.000 description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
- 239000000243 solution Substances 0.000 description 34
- 208000015181 infectious disease Diseases 0.000 description 33
- 239000011780 sodium chloride Substances 0.000 description 28
- 238000005406 washing Methods 0.000 description 26
- 238000002347 injection Methods 0.000 description 20
- 239000007924 injection Substances 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 15
- 241000283973 Oryctolagus cuniculus Species 0.000 description 15
- 241000282414 Homo sapiens Species 0.000 description 14
- 241000124008 Mammalia Species 0.000 description 12
- 230000004071 biological effect Effects 0.000 description 12
- 238000011534 incubation Methods 0.000 description 11
- 241000282412 Homo Species 0.000 description 10
- 238000004113 cell culture Methods 0.000 description 10
- 206010039509 Scab Diseases 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000012286 potassium permanganate Substances 0.000 description 9
- JYLNVJYYQQXNEK-UHFFFAOYSA-N 3-amino-2-(4-chlorophenyl)-1-propanesulfonic acid Chemical compound OS(=O)(=O)CC(CN)C1=CC=C(Cl)C=C1 JYLNVJYYQQXNEK-UHFFFAOYSA-N 0.000 description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 8
- 235000015097 nutrients Nutrition 0.000 description 8
- 229910052708 sodium Inorganic materials 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 238000004114 suspension culture Methods 0.000 description 8
- 230000001018 virulence Effects 0.000 description 8
- 241000233866 Fungi Species 0.000 description 7
- 201000000297 Erysipelas Diseases 0.000 description 6
- 244000025254 Cannabis sativa Species 0.000 description 5
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 5
- 206010067409 Trichophytosis Diseases 0.000 description 5
- 238000009395 breeding Methods 0.000 description 5
- 230000001488 breeding effect Effects 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 5
- 239000002028 Biomass Substances 0.000 description 4
- 244000132059 Carica parviflora Species 0.000 description 4
- 235000014653 Carica parviflora Nutrition 0.000 description 4
- 210000000282 nail Anatomy 0.000 description 4
- 229960002800 prednisolone acetate Drugs 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- AQLJVWUFPCUVLO-UHFFFAOYSA-N urea hydrogen peroxide Chemical compound OO.NC(N)=O AQLJVWUFPCUVLO-UHFFFAOYSA-N 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 206010020565 Hyperaemia Diseases 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- 208000002474 Tinea Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000003308 immunostimulating effect Effects 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 201000010153 skin papilloma Diseases 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 201000009861 cutaneous mycosis Diseases 0.000 description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical compound CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 244000040311 Eucharis candida Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 206010034016 Paronychia Diseases 0.000 description 1
- 241000029132 Paronychia Species 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000006311 Pyoderma Diseases 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 206010043275 Teratogenicity Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 241000893966 Trichophyton verrucosum Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- FHKPLLOSJHHKNU-INIZCTEOSA-N [(3S)-3-[8-(1-ethyl-5-methylpyrazol-4-yl)-9-methylpurin-6-yl]oxypyrrolidin-1-yl]-(oxan-4-yl)methanone Chemical compound C(C)N1N=CC(=C1C)C=1N(C2=NC=NC(=C2N=1)O[C@@H]1CN(CC1)C(=O)C1CCOCC1)C FHKPLLOSJHHKNU-INIZCTEOSA-N 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 210000004905 finger nail Anatomy 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000017555 immunoglobulin mediated immune response Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000211 teratogenicity Toxicity 0.000 description 1
- 210000004906 toe nail Anatomy 0.000 description 1
- 229940055035 trichophyton verrucosum Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/145—Fungal isolates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/16—Yeasts; Culture media therefor
- C12N1/165—Yeast isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
- C12R2001/72—Candida
- C12R2001/725—Candida albicans
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Botany (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP96115954A EP0834322A3 (en) | 1996-10-04 | 1996-10-04 | Mycosis vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP970528A2 true HRP970528A2 (en) | 1998-08-31 |
Family
ID=8223269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR96115954.8A HRP970528A2 (en) | 1996-10-04 | 1997-10-02 | Mycosis vaccine |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6290950B1 (es) |
| EP (2) | EP0834322A3 (es) |
| JP (1) | JP4698771B2 (es) |
| AR (1) | AR008491A1 (es) |
| AT (1) | ATE347372T1 (es) |
| AU (1) | AU740389B2 (es) |
| CA (1) | CA2268138C (es) |
| CO (1) | CO4650185A1 (es) |
| DE (1) | DE69737067T2 (es) |
| DK (1) | DK0956042T3 (es) |
| ES (1) | ES2279546T3 (es) |
| HR (1) | HRP970528A2 (es) |
| PE (1) | PE2399A1 (es) |
| PT (1) | PT956042E (es) |
| RU (1) | RU2219945C2 (es) |
| WO (1) | WO1998015284A2 (es) |
| ZA (1) | ZA978799B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2020959C1 (ru) * | 1991-10-21 | 1994-10-15 | Игорь Дмитриевич Поляков | Вакцина поливак-тм для профилактики и лечения дерматофитозов животных |
| US6720576B1 (en) * | 1992-09-11 | 2004-04-13 | Semiconductor Energy Laboratory Co., Ltd. | Plasma processing method and photoelectric conversion device |
| GB2304347A (en) | 1995-08-11 | 1997-03-19 | Boeringer Ingelheim Vetmedica | Antigenic preparations |
| WO2001015725A1 (en) * | 1998-09-24 | 2001-03-08 | Alpharma As | Vaccine for the protection of a vertebrate animal against fungal skin infection |
| EP1303300B1 (en) * | 2000-06-19 | 2010-08-11 | Hunter Immunology Limited | Compositions and methods for treatment of candidiasis |
| US20040009937A1 (en) * | 2002-01-31 | 2004-01-15 | Wei Chen | Methods and composition for delivering nucleic acids and/or proteins to the respiratory system |
| US20050075298A1 (en) * | 2002-01-31 | 2005-04-07 | Wei Chen | Methods and composition for delivering nucleic acids and/or proteins to the intestinal mucosa |
| US20040043003A1 (en) * | 2002-01-31 | 2004-03-04 | Wei Chen | Clinical grade vectors based on natural microflora for use in delivering therapeutic compositions |
| RU2281110C1 (ru) * | 2005-02-10 | 2006-08-10 | Владислав Николаевич Ласкавый | Лекарственное средство против кандидоза человека для инъекций |
| WO2008036682A2 (en) | 2006-09-18 | 2008-03-27 | Raptor Pharmaceutical Inc. | Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates |
| US20080220023A1 (en) * | 2007-03-08 | 2008-09-11 | Stevens David A | Antifungal vaccines with saccharomyces cerevisiae |
| US20120077778A1 (en) | 2010-09-29 | 2012-03-29 | Andrea Bourdelais | Ladder-Frame Polyether Conjugates |
| HUE055935T2 (hu) | 2016-03-15 | 2022-01-28 | Igor Polyakov | Készítmények pata- és körömbetegségek kezelésére és megelõzésére |
| CA3017673C (en) | 2016-03-15 | 2023-03-07 | Igor Polyakov | New immunobiological products |
| WO2021001540A1 (en) | 2019-07-04 | 2021-01-07 | Proxi Biotech Aps | Detoxification of proteins |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU547928B2 (en) * | 1981-11-03 | 1985-11-14 | Sutka, K. | Antigenic preparation from candida guilliermondii |
| US4762710A (en) * | 1986-06-16 | 1988-08-09 | The United States Of America As Represented By The Department Of Health And Human Services | Novel method of preparing toxoid by oxidation and metal ions |
| CA2011896C (en) * | 1989-04-21 | 2001-05-08 | Mark Werner | Ringworm vaccine |
| DE4007927A1 (de) * | 1990-03-13 | 1991-09-19 | Bayer Ag | Pathogenese-faktoren von dermatophyten |
| US5277904A (en) * | 1990-10-26 | 1994-01-11 | Pier Allan C | Broad spectrum dermatophyte vaccine |
| RU2020959C1 (ru) * | 1991-10-21 | 1994-10-15 | Игорь Дмитриевич Поляков | Вакцина поливак-тм для профилактики и лечения дерматофитозов животных |
| GB9417880D0 (en) * | 1994-09-06 | 1994-10-26 | Auspharm Int Ltd | Vaccine |
| GB2304347A (en) * | 1995-08-11 | 1997-03-19 | Boeringer Ingelheim Vetmedica | Antigenic preparations |
| EP0970966B1 (en) * | 1996-09-04 | 2008-02-20 | Takara Bio Inc. | Fungal antigens and process for producing the same |
-
1996
- 1996-10-04 EP EP96115954A patent/EP0834322A3/en not_active Withdrawn
-
1997
- 1997-09-22 US US09/269,342 patent/US6290950B1/en not_active Expired - Lifetime
- 1997-09-22 JP JP51711998A patent/JP4698771B2/ja not_active Expired - Fee Related
- 1997-09-22 AT AT97942957T patent/ATE347372T1/de active
- 1997-09-22 PT PT97942957T patent/PT956042E/pt unknown
- 1997-09-22 CA CA002268138A patent/CA2268138C/en not_active Expired - Fee Related
- 1997-09-22 WO PCT/EP1997/005181 patent/WO1998015284A2/en active IP Right Grant
- 1997-09-22 RU RU99108989/15A patent/RU2219945C2/ru active
- 1997-09-22 DE DE69737067T patent/DE69737067T2/de not_active Expired - Lifetime
- 1997-09-22 AU AU44604/97A patent/AU740389B2/en not_active Ceased
- 1997-09-22 EP EP97942957A patent/EP0956042B1/en not_active Expired - Lifetime
- 1997-09-22 DK DK97942957T patent/DK0956042T3/da active
- 1997-09-22 ES ES97942957T patent/ES2279546T3/es not_active Expired - Lifetime
- 1997-10-01 ZA ZA9708799A patent/ZA978799B/xx unknown
- 1997-10-02 PE PE1997000879A patent/PE2399A1/es not_active Application Discontinuation
- 1997-10-02 HR HR96115954.8A patent/HRP970528A2/hr not_active Application Discontinuation
- 1997-10-02 CO CO97057661A patent/CO4650185A1/es unknown
- 1997-10-03 AR ARP970104552A patent/AR008491A1/es not_active Suspension/Interruption
Also Published As
| Publication number | Publication date |
|---|---|
| AU4460497A (en) | 1998-05-05 |
| ZA978799B (en) | 1998-04-06 |
| EP0834322A3 (en) | 1998-04-22 |
| WO1998015284A3 (en) | 1999-09-23 |
| CO4650185A1 (es) | 1998-09-03 |
| ES2279546T3 (es) | 2007-08-16 |
| JP4698771B2 (ja) | 2011-06-08 |
| PE2399A1 (es) | 1999-02-10 |
| PT956042E (pt) | 2007-04-30 |
| EP0956042A2 (en) | 1999-11-17 |
| WO1998015284A2 (en) | 1998-04-16 |
| ATE347372T1 (de) | 2006-12-15 |
| EP0956042B1 (en) | 2006-12-06 |
| JP2001503975A (ja) | 2001-03-27 |
| US6290950B1 (en) | 2001-09-18 |
| EP0834322A2 (en) | 1998-04-08 |
| CA2268138A1 (en) | 1998-04-16 |
| AU740389B2 (en) | 2001-11-01 |
| AR008491A1 (es) | 2000-01-19 |
| DE69737067D1 (de) | 2007-01-18 |
| CA2268138C (en) | 2009-01-06 |
| DK0956042T3 (da) | 2007-04-10 |
| DE69737067T2 (de) | 2007-07-05 |
| RU2219945C2 (ru) | 2003-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP970528A2 (en) | Mycosis vaccine | |
| KR100847104B1 (ko) | 아토피 피부염 개선제 조성물 | |
| CN105327344B (zh) | 含有猪圆环病毒2型抗原与副猪嗜血杆菌抗原的疫苗组合物及其制备方法与应用 | |
| JP2001169774A (ja) | 発芽活性化された赤色ガノデルマルシダム胞子及びその製造方法 | |
| EP0304786A2 (de) | Intranasale Impfung von Pferden mit inaktivierten Mikroorganismen oder antigenem Material | |
| US20080241272A1 (en) | Composition for Prevention and Treatment of Stretch Mark Comprising Citric Acid, Zinc and Arginine | |
| EP3429616B1 (en) | Compositions for the treatment and prevention of hoof and claw diseases | |
| KR20170031291A (ko) | 디이노코커스 라디오두란스 유래 엑소폴리사카라이드 및 이를 포함하는 조성물 | |
| TWI743747B (zh) | 育毛髮、生毛髮用外用劑 | |
| JP2001017158A (ja) | 桑黄菌糸体培養用培地組成物及びこれを用いる桑黄菌糸体の培養方法 | |
| WO2018223668A1 (zh) | 一种预防和/或治疗猪圆环病毒感染的二联疫苗组合物及其制备方法和应用 | |
| KR102379274B1 (ko) | 유용성분을 함유하는 기능성 귀리 제조방법 | |
| CN108660115A (zh) | 一种猪圆环病毒3型毒株、及其疫苗组合物、制备方法和应用 | |
| SU955571A1 (ru) | Вакцина ТФ-130 (К) против трихофитии крупного рогатого скота и способ профилактики лечени трихофитии крупного рогатого скота | |
| WO2001015725A1 (en) | Vaccine for the protection of a vertebrate animal against fungal skin infection | |
| KR20180125354A (ko) | 천연 복합 버섯 성분이 함유된 아토피 개선 연고 및 로션 | |
| KR20120039113A (ko) | 돼지 다발성 장막염 예방용 백신 조성물 및 그 제조방법 | |
| Trojacka et al. | Mycotic corneal ulcers caused by Fusarium spp.-available therapeutic options | |
| US20040151726A1 (en) | Novel vaccine for prophylaxis and theraphy in vetirinary and human medicine | |
| CN113692272A (zh) | 弹性蛋白酶活性抑制剂、弹性蛋白酶活性抑制外用剂、及弹性蛋白酶活性抑制饮食用组合物 | |
| Campaign | RESEARCH IN PREVENTIVE MEDICINE | |
| Campaign | Research in Preventive Medicine | |
| CN102988988B (zh) | 一种治疗肺曲霉病的药物组合物 | |
| Strong | Protective inoculation against Asiatic cholera (an experimental study) | |
| EA040511B1 (ru) | Композиции для лечения и предупреждения заболеваний копыт и когтей |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
| ODBC | Application rejected |